Bosentan monohydrate
( DrugBank: Bosentan, Bosentan monohydrate / KEGG DRUG: Bosentan, Bosentan, Bosentan, Bosentan )
4 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 51 | Scleroderma | 2 |
| 84 | Sarcoidosis | 1 |
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 86 | Pulmonary arterial hypertension | 40 |
| 88 | Chronic thromboembolic pulmonary hypertension | 8 |
51. Scleroderma
Clinical trials : 639 / Drugs : 551 - (DrugBank : 157) / Drug target genes : 135 - Drug target pathways : 222
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
84. Sarcoidosis
Clinical trials : 175 / Drugs : 189 - (DrugBank : 80) / Drug target genes : 74 - Drug target pathways : 177
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
86. Pulmonary arterial hypertension
Clinical trials : 1,288 / Drugs : 565 - (DrugBank : 126) / Drug target genes : 81 - Drug target pathways : 191
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
88. Chronic thromboembolic pulmonary hypertension
Clinical trials : 174 / Drugs : 99 - (DrugBank : 19) / Drug target genes : 17 - Drug target pathways : 79
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|